MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-19-2026
Aeglea BioTherapeutics Accounts Payables 2011-2026 | AGLE
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 677 K | 3.32 M | 2.25 M | 3.15 M | 663 K | 389 K | 168 K | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.32 M | 168 K | 1.52 M |
Quarterly Accounts Payables Aeglea BioTherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.16 M | 3.23 M | 3.11 M | 896 K | 1.68 M | 2.85 M | 2.06 M | 677 K | 4.18 M | - | 2.98 M | 3.32 M | 1.86 M | 2.22 M | 1.88 M | 2.25 M | 2.25 M | 2.25 M | 2.25 M | 3.15 M | 3.15 M | 3.15 M | 3.15 M | 663 K | 663 K | 663 K | 663 K | 389 K | 389 K | 389 K | 389 K | 168 K | 168 K | 168 K | 168 K | 176 K | 176 K | 176 K | 176 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.16 M | 168 K | 1.67 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alector
ALEC
|
1.69 M | $ 2.11 | -13.17 % | $ 217 M |  USA |
 |
Acer Therapeutics
ACER
|
3.81 M | - | 2.71 % | $ 14 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
56.8 M | $ 20.52 | -2.12 % | $ 2.59 B | USA |
 |
I-Mab
IMAB
|
570 M | - | - | $ 866 M |  China |
 |
Axsome Therapeutics
AXSM
|
65.5 M | $ 164.13 | 0.15 % | $ 8.17 B | USA |
 |
AgeX Therapeutics
AGE
|
1.41 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
10.6 M | $ 2.49 | -3.11 % | $ 15.6 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.91 M | - | - | $ 26.5 M | USA |
 |
BridgeBio Pharma
BBIO
|
36.2 M | $ 64.24 | -3.37 % | $ 12.3 B | USA |
 |
BioAtla
BCAB
|
3.82 M | $ 0.18 | -26.92 % | $ 8.6 M | USA |
 |
BioCardia
BCDA
|
890 K | $ 1.37 | 6.2 % | $ 29 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
11.6 M | $ 8.61 | -1.66 % | $ 1.78 B | USA |
 |
Black Diamond Therapeutics
BDTX
|
4.01 M | $ 2.4 | -3.04 % | $ 132 M | USA |
 |
Beam Therapeutics
BEAM
|
10.2 M | $ 28.29 | -0.6 % | $ 2.8 B | USA |
 |
ARCA biopharma
ABIO
|
3.46 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
13.4 M | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
601 K | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
1.61 M | - | - | $ 86.2 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
51.7 M | $ 11.47 | -0.43 % | $ 742 M | USA |
 |
Biogen
BIIB
|
432 M | $ 187.68 | -2.16 % | $ 27.5 B | USA |
 |
Akero Therapeutics
AKRO
|
9.03 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
1.28 M | - | 0.23 % | $ 488 M | USA |
 |
BioVie
BIVI
|
2.2 M | $ 1.38 | -0.01 % | $ 2.04 M | USA |
 |
Albireo Pharma
ALBO
|
6.52 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
1.03 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
911 K | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
247 K | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
4.29 M | - | - | $ 2.17 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 60.68 | -1.7 % | $ 11.6 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
3.58 B | $ 62.54 | 0.27 % | $ 127 B | USA |
 |
Benitec Biopharma
BNTC
|
201 K | $ 10.85 | -0.5 % | $ 447 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
750 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
1.58 M | - | - | $ 10.1 M | USA |
 |
Aravive
ARAV
|
8.76 M | - | -13.39 % | $ 1.45 M | USA |
 |
BioXcel Therapeutics
BTAI
|
16 M | $ 1.63 | -2.69 % | $ 4.13 M | USA |
 |
Aptose Biosciences
APTO
|
1.26 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
724 K | - | -39.0 % | $ 4.57 M | USA |
 |
Athira Pharma
ATHA
|
319 K | - | - | $ 269 M | USA |